The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH

Published:2019-11-29 Issue:6 Volume:70 Page:1885-1888
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Loomba Rohit¹²,Adams Leon A.³⁴

Affiliation:

1. Nonalcoholic Fatty Liver Disease Research Center Department of Medicine University of California, San Diego La Jolla CA

2. Division of Gastroenterology Department of Medicine University of California, San Diego La Jolla CA

3. Medical School Faculty of Medical and Health Sciences University of Western Australia Perth WA Australia

4. Department of Hepatology Sir Charles Gairdner Hospital Perth WA Australia

Funder

National Institute of Environmental Health Sciences

National Center for Advancing Translational Sciences

National Institute of Diabetes and Digestive and Kidney Diseases

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.30946

Reference10 articles.

1. NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances

2. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

3. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

4. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials;Sanyal AJ;Hepatology,2019

5. Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Steatotic liver disease in the context of hematological malignancies and anti-neoplastic chemotherapy;Metabolism;2024-11

2. Phenotypes of Metabolic Dysfunction–Associated Steatotic Liver Disease–Associated Hepatocellular Carcinoma;Clinical Gastroenterology and Hepatology;2024-09

3. Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease;Journal of Clinical and Translational Hepatology;2024-07-31

4. Liver Tissue Proteins Improve the Accuracy of Plasma Proteins as Biomarkers in Diagnosing Metabolic Dysfunction‐Associated Steatohepatitis;PROTEOMICS – Clinical Applications;2024-07-28

5. Development of Zalfermin, a Long-Acting Proteolytically Stabilized FGF21 Analog;Journal of Medicinal Chemistry;2024-07-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3